Story thread · 2 reports / 2 sources
XYRA Announces First Patient Dosed in Europe in the Phase 2/3 HARBOR-AF Study of Budiodarone in Paroxysmal and Persistent Atrial Fibrillation
financialpost.com · 15d
LOS ALTOS, California, Aug. 31, 2026 (GLOBE NEWSWIRE) — Open-label, dose-escalation study using cardiac rhythm data from implantable and wearable AF monitors allows the treating physician to titrate the dose of budiodarone monthly. First European patient dosed in CLN-209 (HARBOR-AF) Study is the first to titrate an antiarrhythmic drug against continuously monitored AF burden (AFB) […]
First report: XYRA Announces First Patient Dosed in Europe in the Phase 2/3 HARBOR-AF Study of Budiodarone in Paroxysmal and Persistent Atrial Fibrillation — thestar.com, 15d
The conversation · 0
Sign in to join the conversation.
No comments yet — start the thread.